看來載入頁面時發生了錯誤.
我們的團隊已收到通知，但若此問題持續，請透過電郵支援widget工具聯絡我們。
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM EBIT Multiple | -2.2x - -2.5x | -2.4x |
| Selected Fwd EBIT Multiple | -2.2x - -2.5x | -2.4x |
| Fair Value | €11.21 - €11.93 | €11.57 |
| Upside | -0.8% - 5.6% | 2.4% |
| Benchmarks | Ticker | Full Ticker |
| BioMarin Pharmaceutical Inc. | BMRN | NasdaqGS:BMRN |
| Ionis Pharmaceuticals, Inc. | IONS | NasdaqGS:IONS |
| Intellia Therapeutics, Inc. | NTLA | NasdaqGM:NTLA |
| BioCryst Pharmaceuticals, Inc. | BCRX | NasdaqGS:BCRX |
| CSL Limited | CMXH.F | PINC:CMXH.F |
| KalVista Pharmaceuticals, Inc. | 4XC1 | DB:4XC1 |
| - | - | - |
| Select LTM EBIT Multiple | |||||||
| Benchmark Companies | |||||||
| BMRN | IONS | NTLA | BCRX | CMXH.F | 4XC1 | ||
| NasdaqGS:BMRN | NasdaqGS:IONS | NasdaqGM:NTLA | NasdaqGS:BCRX | PINC:CMXH.F | DB:4XC1 | ||
| Historical EBIT Growth | |||||||
| 5Y CAGR | NM- | NM- | NM- | NM- | 9.2% | NM- | |
| 3Y CAGR | NM- | NM- | NM- | NM- | 7.6% | NM- | |
| Latest Twelve Months | 254.5% | -28.0% | -3.7% | 140.6% | 3.9% | -46.6% | |
| Historical EBIT Profit Margin | |||||||
| 5 Year Average Margin | 3.5% | -34.1% | -759.8% | -147.4% | 28.1% | -747.3% | |
| Prior Fiscal Year | 7.7% | -42.4% | -1420.5% | -29.8% | 25.7% | NA | |
| Latest Fiscal Year | 20.0% | -67.4% | -923.1% | -0.3% | 26.3% | NA | |
| Latest Twelve Months | 24.3% | -65.9% | -923.1% | 6.8% | 26.6% | NA | |
| Current Trading Multiples | |||||||
| EV / LTM Revenue | 3.48x | 6.82x | -1.12x | 5.30x | 6.13x | NA | |
| EV / LTM EBITDA | 12.7x | -10.6x | 0.1x | 70.4x | 19.4x | -2.4x | |
| EV / LTM EBIT | 14.3x | -10.4x | 0.1x | 77.4x | 23.0x | -2.3x | |
| Low | Mid | High | |||||
| Benchmark EV / LTM EBIT | -10.4x | 14.3x | 77.4x | ||||
| Historical EV / LTM EBIT | -11.4x | -2.7x | -1.2x | ||||
| Selected EV / LTM EBIT | -2.2x | -2.4x | -2.5x | ||||
| (x) LTM EBIT | (181) | (181) | (181) | ||||
| (=) Implied Enterprise Value | 407 | 428 | 450 | ||||
| (-) Non-shareholder Claims * | 247 | 247 | 247 | ||||
| (=) Equity Value | 654 | 676 | 697 | ||||
| (/) Shares Outstanding | 49.7 | 49.7 | 49.7 | ||||
| Implied Value Range | 13.16 | 13.59 | 14.03 | ||||
| FX Rate: USD/EUR | 1.1 | 1.1 | 1.1 | Market Price | |||
| Implied Value Range (Trading Cur) | 11.61 | 11.99 | 12.37 | 11.30 | |||
| Upside / (Downside) | 2.7% | 6.1% | 9.5% | ||||
| Equity Waterfall | |||||||
| Benchmark Companies | |||||||
| (in millions) | BMRN | IONS | NTLA | BCRX | CMXH.F | 4XC1 | |
| Enterprise Value | 10,724 | 5,134 | 195 | 2,828 | 89,039 | 390 | |
| (+) Cash & Short Term Investments | 1,272 | 2,148 | 602 | 321 | 1,524 | 253 | |
| (+) Investments & Other | 507 | 41 | 287 | 0 | 0 | 0 | |
| (-) Debt | (602) | (1,969) | (210) | (841) | (11,964) | (6) | |
| (-) Other Liabilities | 0 | 0 | 0 | 0 | (1,987) | 0 | |
| (-) Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 | |
| (-) Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| Value of Common Equity | 11,902 | 5,355 | 874 | 2,308 | 76,612 | 637 | |
| (/) Shares Outstanding | 191.8 | 159.2 | 103.5 | 209.2 | 484.2 | 49.7 | |
| Implied Stock Price | 62.06 | 33.65 | 8.44 | 11.03 | 158.22 | 12.81 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.13 | |
| Implied Stock Price (Trading Cur) | 62.06 | 33.65 | 8.44 | 11.03 | 158.22 | 11.30 | |
| Trading Currency | USD | USD | USD | USD | USD | EUR | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.13 | |